iShares Genomics Immunology and Healthcare ETF

Merck's Winrevair Must Show Walking Distance Improvements to Build Confidence

Traders Pessimistic on Merck Stock, Abnormal Options Trading Occurs

Analysts at Morgan Stanley and Barclays Maintain Buy Rating on Bayer

Roche's Breast Cancer Treatment Study Fails to Reach Primary Endpoint

Roche Signs MoU with Egyptian Health Authority for National Digital Pathology Project

Modern Wealth Management Increases Holdings in Merck

Merck CEO Garijo Reiterates Importance of Chinese Market and Discusses Collaboration Opportunities

Roche's Xofluza Receives Expanded Indication Approval from China's NMPA

Roche Holding's Fenebrutinib Shows Positive Results in Multiple Sclerosis Phase 3 Trials

Evercore ISI Maintains Hold Rating on Moderna, BofA Reiterates Sell

Bayer Aktiengesellschaft released FY2025 Q4 earnings on March 4 Pre-Market (EST), actual revenue USD 13.43 B (forecast USD 13.27 B), actual EPS USD -4.4916

Bayer Aktiengesellschaft released FY2025 earnings on March 4 Pre-Market EST, actual revenue USD 52.51 B (forecast USD 53.59 B), actual EPS USD -4.2456

Moderna expects total available liquidity to reach $5.4B to $5.9B by the end of 2026

Moderna's Combo COVID-Flu Vaccine mCombriax Ready for EMA Approval

Elo Mutual Increases Holdings in Merck

Roche's Fenebrutinib Phase III Trial Shows 51% Reduction in Relapse Rate

Merck Announces Positive Results for KEYTRUDA and WELIREG Combination Therapy in Phase 3 Trial

Whales Bearish on Moderna Stock

Merck Reduces Staff at US HPV Vaccine Plant

Moderna's MCOMBRIAX Combined COVID-Flu Vaccine Aims For EU Markets in 2026/2027 Flu Season

bioAffinity Tech

iSpecimen

eLong Power

CXApp

Korro Bio

DevvStream

T-REX 2X Long UPXI Daily Target ETF

Oncology Institute

Silvaco

EL Pollo Loco

IDNA

PLNT

MoveFitRx has announced the launch of a health technology platform aimed at integrating exercise into clinical care as a validated prescription. This HIPAA-compliant portal allows physicians to prescribe exercise based on patient diagnoses, addressing the disconnect between exercise and formal healthcare. The platform focuses on key health areas and verifies patient adherence digitally. A clinical pilot is set for Spring 2026 in San Diego, coinciding with strategic briefings at the Health & Fitness Association National Conference. MoveFitRx aims to treat exercise with the same rigor as pharmaceutical interventions.

prnewswire

Health Care Select Sector SPDR

iShares US Healthcare Providers

VG Health

SPDR S&P Health

iShares Global Healthcare

Planet Fitness - CL

08:31 ETMoveFitRx Launches Clinical Intelligence Layer to Establish Exercise as a Medical Standard of Care

LABU

ARKG

SBIO

ISPC

The Oncology Institute (TOI) shares rose 14.7% to $3.01 in pre-market trading after reporting better-than-expected Q4 results, with losses of 6 cents per share against an estimate of 9 cents. Quarterly sales reached $141.957 million, surpassing the $139.775 million estimate. Other notable pre-market gainers included iSpecimen Inc (up 46.6%), PayPay Corporation (up 37.7%), and EON Resources Inc (up 34.6%). Conversely, Immutep Limited saw a significant drop of 77.3% in pre-market trading.

benzinga_article

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Why Oncology Institute Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Shares of iSpecimen Inc. (ISPC) surged 62% to $0.36 after the launch of its AI-powered Inventory Agent, aimed at modernizing biospecimen procurement. This tool utilizes large language models to efficiently match specimen requests with available inventory while maintaining expert oversight for quality. CEO Katie Field highlighted the launch as a significant milestone, enhancing access to critical samples for researchers. iSpecimen plans to further expand its AI capabilities, including regulatory monitoring and workflow automation. The stock has fluctuated between $0.22 and $3.18 over the past year, closing at $0.22 before the surge.

nasdaq

ISpecimen Rallies On Biospecimen Marketplace Expansion

Biodesix (NASDAQ: BDSX) is focused on developing diagnostic tests for lung disease, with five lung tests currently on the market, all covered by Medicare. CFO Robin Cowie highlighted the company's emphasis on improving patient outcomes and addressing inefficiencies in lung cancer care. Biodesix reported an 81% gross margin and achieved adjusted EBITDA profitability in Q4 of last year. The company is prioritizing growth in its commercial organization and expanding its biopharma services, with increasing demand and a strong backlog.

Market Beat

Biodesix

iShares US Medical Devices

Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare | GH Stock News

StockTitan

Guardant Health

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare | GH Stock News

iSpecimen (ISPC) shares surged nearly 43% in after-hours trading to $0.32 following the launch of its AI-powered Inventory Agent, designed to automate biospecimen request matching. Despite a 6.67% decline during regular trading, the announcement was hailed by CEO Katie Field as a significant milestone. The company plans further AI-driven features, although ISPC has seen an 82.77% decline over the past year and is currently at its annual low, indicating a need for clear recovery signals before investor action.

iSpecimen (ISPC) Stock Rockets 43% After Hours — Here's Why It's Trending

PYPG

IBBQ

Cathie Wood's ARK Invest ETFs made significant portfolio adjustments on March 12, investing over $10 million in CRISPR Therapeutics (CRSP) and PayPay Corp. (PAYP), while reducing stakes in Teradyne (TER) and Ionis Pharmaceuticals (IONS). The largest purchase was 112,815 shares of CRISPR for approximately $5.63 million, followed by 275,000 shares of PayPay valued at $4.4 million. ARK also sold shares in several other companies, continuing a trend of trimming positions in certain stocks.

- Cathie Wood's ARK Invest ETFs adjusted their portfolio on March 12, increasing investments in biotech and digital payment companies while reducing stakes in certain healthcare and semiconductor stocks.  
- Major purchases included 112,815 shares of CRISPR Therapeutics for $5.63 million and 275,000 shares of PayPal for approximately $4.4 million, emphasizing a focus on gene-editing technology and digital payments.  
- On the selling side, ARK reduced its stakes in companies like Teradyne and Ionis Pharmaceuticals, reflecting a strategic reshaping of its investment portfolio.

Tip Ranks

Leverage Shares 2X Long PYPL Daily ETF

Ionis Pharma

Invesco Nasdaq Biotechnology ETF

Ark Innovation ETF

Paypal

iShares US Pharma

Wisdomtree BioRevolution Fund ETF

CRISPR Therap

Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS

CRISPR Therapeutics AG's CEO, Samarth Kulkarni, sold 9,798 shares on March 11, 2026, for $52.8 each, totaling $517,334. After the sale, he owns 235,558 shares. The transaction was to cover tax obligations from restricted stock units, as per the company's RSU Settlement Policy. This information is based on SEC Form 4 filings.

TradingView

CRISPR Therapeutics AG CEO Samarth Kulkarni Sells Shares

Illumina Inc. (ILMN) shares fell 4.89% to $115.56 on Thursday, marking the ninth consecutive day of losses. The stock is currently 25.70% below its 52-week high of $155.53. In comparison, Labcorp Holdings Inc. dropped 2.78%, Charles River Laboratories fell 9.62%, while Quest Diagnostics saw a slight increase of 0.16%. Overall, the S&P 500 Index and Dow Jones Industrial Average also experienced declines of 1.52% and 1.56%, respectively, during a challenging trading session.

Dow Jones

Charles River Laboratorie

Quest Diagnostics

Labcorp

Illumina

Illumina Inc. Stock Underperforms Thursday When Compared To Competitors

iSpecimen shares are trading higher after the company announced the launch of its new AI-powered Inventory Agent.

Champions Oncology, Inc. reported third-quarter fiscal 2026 revenue of $16.6 million, a 32% increase in study service revenue year-over-year, despite a slight decline in total revenue compared to the previous year. The company achieved positive adjusted EBITDA of $574,000, marking its third consecutive quarter of profitability. CEO Robert Brainin highlighted strong operational performance and confidence in long-term growth, while CFO David Miller noted a modest revenue decline due to the absence of a prior-year data license transaction. Total costs rose significantly, impacting net income, which was a loss of $279,000 for the quarter.

Acceswire

Champions Oncology

Champions Oncology Reports Revenue of $16.6 Million

Daversa has promoted nine leaders to Managing Director, including Connor Freeborn, Nicole Kaylor, and Emma Mango, among others. This decision reflects their performance and expertise in executive searches for high-growth companies across various sectors such as defense, AI, and healthcare. Founder Paul Daversa emphasized their ability to build trust and deliver results in critical environments. The promotions highlight Daversa's commitment to partnering with ambitious founders and shaping the future of leadership talent.

MorningStar

Daversa Promotes Nine to Managing Director, Strengthening Leadership Across Critical Growth Sectors

Cathie Wood's Ark Invest has purchased shares of GeneDx Holdings Corp, a small-cap diagnostics company, for seven consecutive trading days. The company, with a market cap of $2.5 billion, has shown strong financial performance, beating earnings and revenue estimates for multiple quarters. Ark's ETFs, ARKK and ARKG, have increased their holdings significantly, indicating potential investor interest. GeneDx reported a 27% year-over-year revenue growth in Q4, with guidance suggesting revenue could reach $540-$555 million in 2026. Despite a recent stock decline, the company's expansion into new markets may present growth opportunities.

GeneDx

Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note?

iShares Genomics Immunology and Healthcare ETF(IDNA.US)

08:31 ETMoveFitRx Launches Clinical Intelligence Layer to Establish Exercise as a Medical Standard of Care

Why Oncology Institute Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

ISpecimen Rallies On Biospecimen Marketplace Expansion

Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare | GH Stock News